|
Valoración de DCF de Collegium Pharmaceutical, Inc. (Coll)
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Collegium Pharmaceutical, Inc. (COLL) Bundle
¡Optimice su tiempo y mejore la precisión con nuestra calculadora DCF [símbolo]! Utilizando datos reales de Collegium Pharmaceutical, Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y valorar [compañía] como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 296.7 | 310.0 | 276.9 | 463.9 | 566.8 | 685.1 | 828.2 | 1,001.1 | 1,210.2 | 1,462.9 |
| Revenue Growth, % | 0 | 4.49 | -10.69 | 67.56 | 22.17 | 20.88 | 20.88 | 20.88 | 20.88 | 20.88 |
| EBITDA | -6.0 | 118.1 | 86.6 | 168.8 | 308.3 | 216.6 | 261.9 | 316.6 | 382.7 | 462.6 |
| EBITDA, % | -2.03 | 38.09 | 31.27 | 36.38 | 54.4 | 31.62 | 31.62 | 31.62 | 31.62 | 31.62 |
| Depreciation | 15.8 | 61.6 | 68.9 | 134.4 | 149.3 | 144.4 | 174.6 | 211.0 | 255.1 | 308.4 |
| Depreciation, % | 5.32 | 19.87 | 24.9 | 28.97 | 26.33 | 21.08 | 21.08 | 21.08 | 21.08 | 21.08 |
| EBIT | -21.8 | 56.5 | 17.6 | 34.4 | 159.1 | 72.2 | 87.3 | 105.5 | 127.6 | 154.2 |
| EBIT, % | -7.35 | 18.21 | 6.37 | 7.41 | 28.07 | 10.54 | 10.54 | 10.54 | 10.54 | 10.54 |
| Total Cash | 170.0 | 174.1 | 186.4 | 173.7 | 310.5 | 374.1 | 452.2 | 546.7 | 660.8 | 798.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 73.0 | 83.3 | 105.8 | 183.1 | 179.5 | 220.4 | 266.4 | 322.0 | 389.3 | 470.6 |
| Account Receivables, % | 24.59 | 26.88 | 38.23 | 39.47 | 31.68 | 32.17 | 32.17 | 32.17 | 32.17 | 32.17 |
| Inventories | 9.6 | 15.6 | 17.4 | 46.5 | 32.3 | 41.5 | 50.2 | 60.7 | 73.3 | 88.6 |
| Inventories, % | 3.25 | 5.04 | 6.28 | 10.02 | 5.7 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Accounts Payable | 6.2 | 10.0 | 4.2 | 3.5 | 8.7 | 12.5 | 15.1 | 18.3 | 22.1 | 26.7 |
| Accounts Payable, % | 2.11 | 3.23 | 1.51 | 0.75313 | 1.53 | 1.83 | 1.83 | 1.83 | 1.83 | 1.83 |
| Capital Expenditure | -6.4 | -373.8 | -1.9 | -1.6 | -.5 | -141.5 | -171.1 | -206.8 | -250.0 | -302.2 |
| Capital Expenditure, % | -2.17 | -120.57 | -0.70214 | -0.34962 | -0.08133854 | -20.66 | -20.66 | -20.66 | -20.66 | -20.66 |
| Tax Rate, % | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 | 36.41 |
| EBITAT | -7.8 | 54.8 | -373.9 | 29.8 | 101.1 | 40.9 | 49.4 | 59.8 | 72.2 | 87.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -74.8 | -270.0 | -337.0 | 55.5 | 272.9 | -2.5 | .8 | 1.0 | 1.2 | 1.5 |
| WACC, % | 7.33 | 10.02 | 5.74 | 9.57 | 8.55 | 8.24 | 8.24 | 8.24 | 8.24 | 8.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1.1 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 2 | |||||||||
| Terminal Value | 36 | |||||||||
| Present Terminal Value | 24 | |||||||||
| Enterprise Value | 25 | |||||||||
| Net Debt | 435 | |||||||||
| Equity Value | -410 | |||||||||
| Diluted Shares Outstanding, MM | 42 | |||||||||
| Equity Value Per Share | -9.82 |
What You Will Gain
- Pre-Filled Financial Model: Collegium Pharmaceutical’s actual data provides an accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results immediately as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Adaptable and Reusable: Designed for versatility, enabling repeated use for in-depth forecasts.
Key Features
- 🔍 Real-Life COLL Financials: Pre-filled historical and projected data for Collegium Pharmaceutical, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Collegium’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Collegium’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Collegium Pharmaceutical data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Collegium Pharmaceutical’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Collegium Pharmaceutical, Inc. (COLL)?
- Accuracy: Utilizes real Collegium financials to ensure precise data.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected by CFOs.
- User-Friendly: Intuitive interface suitable for users without extensive financial modeling skills.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Collegium Pharmaceutical, Inc. (COLL) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Collegium Pharmaceutical, Inc. (COLL).
- Consultants: Deliver professional valuation insights on Collegium Pharmaceutical, Inc. (COLL) to clients quickly and accurately.
- Business Owners: Understand how companies like Collegium Pharmaceutical, Inc. (COLL) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Collegium Pharmaceutical, Inc. (COLL).
What the Template Contains
- Historical Data: Includes Collegium Pharmaceutical’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Collegium Pharmaceutical’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Collegium Pharmaceutical’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.